Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78

by Bojana Borjan, Bojana Borjan, Johann Kern, Normann Steiner, Eberhard Gunsilius, Dominik Wolf, Gerold Untergasser, Gerold Untergasser
Published 2020-01-01

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

by Wolfgang Willenbacher, Andreas Seeber, Normann Steiner, Ella Willenbacher, Zoran Gatalica, Jeff Swensen, Jeffery Kimbrough, Semir Vranic
Published 2018-07-01

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.

by Normann Steiner, Roman Hajek, Sabina Sevcikova, Bojana Borjan, Karin Jöhrer, Georg Göbel, Gerold Untergasser, Eberhard Gunsilius
Published 2017-01-01

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets.

by Normann Steiner, Udo Müller, Roman Hajek, Sabina Sevcikova, Bojana Borjan, Karin Jöhrer, Georg Göbel, Andreas Pircher, Eberhard Gunsilius
Published 2018-01-01

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis

by Normann Steiner, Karin Jöhrer, Selina Plewan, Andrea Brunner-Véber, Georg Göbel, David Nachbaur, Dominik Wolf, Eberhard Gunsilius, Gerold Untergasser
Published 2020-08-01

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

by Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth
Published 2021-09-01